SHTDF (Sinopharm Group Co) Momentum Rank: 9 (As of Jul. 21, 2026) — 125% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHTDF Sinopharm Group Co Ltd SHTDF
78 GF Score
Price $2.13
GF Value $2.58
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Sinopharm Group Co Momentum Rank?

Sinopharm Group Co SHTDF -6.74% 78 Momentum Rank is 9 as of Jul. 21, 2026, which is 125% above its 10-year median of 4.00. GuruFocus rates SHTDF with a GF Score™ of 78/100 and a GF Value™ of $2.58 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Sinopharm Group Co has the Momentum Rank of 9.

Momentum Rank measures the strength and persistence of a stock's price movement over time, rated on a scale of 1 to 10.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

A higher score reflects strong price momentum and indicates greater potential for superior performance. Conversely, a lower score indicates that momentum is either too high or too low, and stocks tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Sinopharm Group Co Momentum Rank Related Terms

SHTDF vs MCK, CAH, COR: Momentum Rank Comparison

For the Medical Distribution subindustry, Sinopharm Group Co's Momentum Rank, along with its competitors' market caps and Momentum Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sinopharm Group Co Momentum Rank vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's Momentum Rank distribution charts can be found below:

* The bar in red indicates where Sinopharm Group Co's Momentum Rank falls into.


SHTDF
78GF Score
Sinopharm Group Co Ltd SHTDF
Momentum Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Momentum Rank →
What does a Momentum Rank of 9 mean?
Sinopharm Group Co (SHTDF) has a Momentum Rank of 9 as of Jul. 21, 2026. Momentum Rank is determined using the standardized momentum ratio, measuring the speed and velocity of price changes in a stock. View historical data on Sinopharm Group Co and its competitors. This is 125% above median its historical median of 4.00. Over the past decade, Sinopharm Group Co's Momentum Rank has ranged from 1.00 to 10.00.
Is Sinopharm Group Co's Momentum Rank too high?
Sinopharm Group Co's current Momentum Rank of 9 is 125% above median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, Sinopharm Group Co has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinopharm Group Co's Momentum Rank compare to MCK and CAH?
Sinopharm Group Co's Momentum Rank of 9 can be compared against companies in the Medical Distribution industry. Historically, Sinopharm Group Co's own Momentum Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Momentum Rank for a Medical Distribution company?
A good Momentum Rank depends on the Medical Distribution industry context. However, Momentum Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Momentum Rank mean?
A high Momentum Rank can signal that a stock is expensive relative to its fundamentals. Momentum Rank is determined using the standardized momentum ratio, measuring the speed and velocity of price changes in a stock. View historical data on Sinopharm Group Co and its competitors. Sinopharm Group Co's current Momentum Rank is 9, which is 125% above median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinopharm Group Co stock overvalued right now?
Based on GuruFocus' analysis, Sinopharm Group Co (SHTDF) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.58, compared to a current price of $2.13 — trading 17.3% below its estimated fair value. The current Momentum Rank is 9, which is 125% above median its 10-year median of 4.00. Sinopharm Group Co's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Momentum Rank calculated?
Momentum Rank is calculated from a company's financial statements. For Sinopharm Group Co (SHTDF), the current Momentum Rank is 9 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sinopharm Group Co (SHTDF) Overvalued in 2026?

Based on GuruFocus' analysis, Sinopharm Group Co stock appears to be undervalued. The current stock price of $2.13 is trading 17.3% below its estimated GF Value™ of $2.58. GuruFocus considers Sinopharm Group Co to be Modestly Undervalued.

Key valuation signals for SHTDF:

  • Momentum Rank: 9 (125% above median its 10-year median of 4.00)
  • GF Value™: $2.58 vs. price of $2.13 (17.3% below fair value)
  • GF Score™: 78/100 with 4 warning signs

No single metric tells the full story. See the SHTDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sinopharm Group Co Business Description

Address No. 385, East Longhua Road, Sinopharm Group Building, Huangpu District, Shanghai, CHN, 200023
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.
78GF Score

Get the complete analysis for SHTDF

Momentum Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.13
Price
$2.58
GF Value